NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I had a chance to listen to the Charles River Laboratories (CRL) Q1 2023 Earnings Conference Call, which was held yesterday, 5/11/2023. During the Q&A part of this call, CRL spoke about their CDMO business, and their expectations for growth during the second half of 2023, and continuing into 2024.

https://edge.media-server.com/mmc/p/evrd3zta

From the 1:03:30 minute mark to the 1:06:10 minute mark of this recording, CRL addressed the new cell therapy CDMO business they are expecting at CRL Memphis facility (f/k/a Cognate). They also indicated that they have clients who are expecting to file for regulatory approvals with the FDA and EMA soon. Some of those clients have already reserved clean rooms with CRL in anticipation of FDA and EMA approvals. Also, some clients have asked CRL to prepare for FDA audits of their Memphis facility.

My hope and belief is that 1 of these new CDMO clients is NWBio, and they are preparing for DCVax-L regulatory approvals in the US, Canada, UK, and the EU.